Study:
Phase II Clinical Trial Of Patients With High-Grade Glioma Treated With Intra-Arterial Carboplatin-Based Chemotherapy, Randomized To Treatment With Or Without Delayed Intravenous Sodium Thiosulfate As A Potential Chemoprotectant Against Severe Thrombocytopenia
Rationale:
Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and
etoposide phosphate, work in different ways to stop tumor cells from dividing so they stop
growing or die. Combining more than one drug (combination chemotherapy) and giving them in
different ways may kill more tumor cells. Chemoprotective drugs, such as sodium thiosulfate,
may protect blood platelets from the side effects of chemotherapy.
Purpose:
This randomized phase II trial is studying combination chemotherapy and sodium
thiosulfate to see how well they work compared to combination chemotherapy alone in treating
patients with high-grade glioma.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
Brain and Central Nervous System Tumors
Thrombocytopenia |
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: etoposide phosphate
Drug: sodium thiosulfate |
Phase 2 |
Verified by
Oregon Health and Science University
June, 2009
Sponsored by: Oregon Health and Science University
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00075387
Study Type: Interventional
Study Design: Supportive Care, Randomized, Active Control
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Edward A. Neuwelt, MD., Principal Investigator